Can't fill your Cyltezo prescription? Explore real alternatives including other adalimumab biosimilars and TNF inhibitors available in 2026.
If you've been prescribed Cyltezo Pen 40 Mg/0.4 Ml Starter Pack and you're unable to fill your prescription — whether because of availability issues, insurance restrictions, or cost — you have options. Several alternatives exist that work the same way and treat the same conditions.
In this article, we'll explain what Cyltezo is, how it works, and walk through the most practical alternatives available in 2026.
Cyltezo is the brand name for adalimumab-dbll, manufactured by Boehringer Ingelheim. It was the first adalimumab biosimilar to receive FDA approval (in 2017) and the first to earn interchangeable status with Humira.
The Starter Pack is designed for patients beginning Cyltezo therapy. It contains prefilled pens for subcutaneous injection at a strength of 40 mg/0.4 mL. The formulation is citrate-free, which may cause less stinging at the injection site compared to older adalimumab formulations.
Cyltezo is prescribed for autoimmune and inflammatory conditions including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis.
Cyltezo is a TNF-alpha inhibitor. TNF-alpha (tumor necrosis factor-alpha) is a protein your immune system produces that triggers inflammation. In autoimmune conditions, your body makes too much TNF-alpha, leading to chronic inflammation that damages joints, skin, and organs.
Cyltezo works by binding to TNF-alpha and blocking it from attaching to receptors on your cells. This reduces the inflammatory response and helps control symptoms like joint pain, swelling, skin plaques, and digestive inflammation.
All adalimumab products — Humira and its biosimilars — work through this same mechanism. That's why switching between them is generally straightforward from a clinical standpoint.
If you can't get Cyltezo, these are the most realistic alternatives to discuss with your doctor:
Humira by AbbVie is the original adalimumab product that Cyltezo is biosimilar to. It has been on the market since 2003 and has the longest track record of any adalimumab product. Humira is available in multiple forms including prefilled pens and syringes.
While Humira's list price is higher than most biosimilars (approximately $6,900 to $7,200 per month without insurance), AbbVie offers significant copay assistance programs that can bring out-of-pocket costs down substantially for commercially insured patients.
Why consider it: Widest availability, extensive patient support programs, longest clinical track record.
Amjevita by Amgen is another FDA-approved interchangeable adalimumab biosimilar. Like Cyltezo, it can be substituted at the pharmacy level in many states. Amjevita is available in both a standard-concentration and a high-concentration citrate-free formulation.
Amgen has aggressively priced Amjevita to compete in the market, and it has gained significant formulary placement with major PBMs. This means it may be easier to fill through your insurance than Cyltezo.
Why consider it: Interchangeable status, strong insurance coverage, competitive pricing typically 5-10% below Humira's list price.
Hadlima is manufactured by Samsung Bioepis and marketed by Organon. It's an adalimumab biosimilar available as a prefilled syringe and autoinjector. Hadlima has gained formulary placement with several major PBMs and may be your insurance plan's preferred adalimumab product.
Why consider it: Good insurance coverage, available in autoinjector form, competitive pricing.
Hyrimoz by Sandoz is another adalimumab biosimilar that's been on the market since 2023. It's available as a prefilled pen (called the Sensoready pen) and prefilled syringe. Sandoz, as a major generics and biosimilars company, has pushed for broad availability.
Why consider it: Available in pen form similar to Cyltezo, broad distribution through Sandoz's established pharmacy network.
Additional adalimumab biosimilars include Yusimry (adalimumab-aqvh) by Coherus BioSciences and Simlandi (adalimumab-ryvk) by Teva, which also has interchangeable status. Your doctor and insurance plan can help determine which option is most accessible and affordable for you.
If adalimumab products in general aren't working for you or aren't available, your doctor may consider other TNF inhibitors or biologic medications, depending on your condition:
These are different drug classes, so switching to them requires your doctor's guidance and may involve different monitoring.
If you and your doctor decide to switch from Cyltezo to an alternative:
Not being able to fill your Cyltezo prescription is stressful, especially when you depend on it to manage a chronic condition. But the availability of multiple adalimumab biosimilars in 2026 means you have real alternatives that work the same way.
Talk to your doctor about which option your insurance covers best. Use Medfinder to check availability for any of these medications. And don't delay treatment — the most important thing is staying on an effective TNF inhibitor, regardless of the specific brand.
For more information, read our articles on how to find Cyltezo in stock or the latest Cyltezo shortage update.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
